RUC-4 manufacturers
- Zalunfiban
-
- $2800.00
-
2026-07-27
- CAS:1448313-27-6
- Purity:
- Supply Ability: 10g
|
| Product Name: | RUC-4 | | Synonyms: | CPD1217;RUC-4;Acetamide, 2-amino-N-[5-[5-oxo-7-(1-piperazinyl)-5H-1,3,4-thiadiazolo[3,2-a]pyrimidin-2-yl]-3-pyridinyl]-;2-Amino-N-[5-[5-oxo-7-(1-piperazinyl)-5H-1,3,4-thiadiazolo[3,2-a]pyrimidin-2-yl]-3-pyridinyl]acetamide;2-Amino-N-(4-(5-oxo-7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyridin-2-yl)acetamide;Zalunfiban | | CAS: | 1448313-27-6 | | MF: | C16H18N8O2S | | MW: | 386.43 | | EINECS: | | | Product Categories: | | | Mol File: | 1448313-27-6.mol |  |
| | RUC-4 Chemical Properties |
| density | 1.702±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 12.449±0.70(predicted) |
| | RUC-4 Usage And Synthesis |
| Uses | Zalunfiban (RUC-4) is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban can be used for the research of myocardial infarction (MI)[1]. | | in vivo | Zalunfiban (1~3.86 mg/kg; s.c.; 24 hours) makes platelet aggregation performed[1].
Zalunfiban (1~3.86 mg/kg; i.m.; 4.5 hours) leads to the onset of high-grade inhibition of platelet aggregation within 15-30 minutes that lasted from ~2 to >4.5 hours in a dose dependent manner[1]. | Animal Model: | Cynomolgus Monkey | | Dosage: | 1~3.86 mg/kg (Pharmacokinetic Analysis) | | Administration: | S.c.; 24 hours | | Result: | Platelet aggregation was performed.
|
| | References | [1] Vootukuri S, et al. Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. J Clin Transl Sci. 2019;3(2-3):65-74. DOI:10.1017/cts.2019.382 |
| | RUC-4 Preparation Products And Raw materials |
|